Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | F. Zammarchi, S. Chivers, D.G. Williams, L. Adams, M. Mellinas-Gomez, F. Tyrer, S. Corbett, F. D’Hooge, S. Dissanayake, S. Sims, K. Havenith, P.W. Howard, J.A. Hartley, P.H. Van Berkel | ||||||||||||
Title | 62 - ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers | ||||||||||||
|
|||||||||||||
URL | http://www.sciencedirect.com/science/article/pii/S0959804916326624 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADCT-502 | ADCT502|ADCT 502 | HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 | ADCT-502 is an antibody-drug conjugate (ADC) comprising a ERBB2 (HER2) targeted antibody linked to a pyrrolobenzodiazepine dimer, which delivers the drug to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased tumor growth (Eur J Cancer, 2016, Vol. 69, Supp 1, S28, PMID: 30931493). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|